DCGO
DocGo Inc.
DCGO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over DCGO overall, supported by stronger fundamentals and lower modeled downside.
DCGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
DCGO's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCGO PE Valuation
DCGO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DCGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DCGO's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over DCGO on the outlook, with more favorable revenue expectations.
DCGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.84 | -$1.33 |
| Q2 2026 | -$1.95 | -$1.77 |
| Q1 2026 | -$1.90 | -$1.89 |
| Q4 2025 | -$1.84 | -1122% |
| Q3 2025 | -$0.51 | -289% |
| Q2 2025 | -$0.18 | -167% |
| Q1 2025 | -$0.01 | -105% |
| Q4 2024 | $0.18 | +200% |
DCGO lost $1.84 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DCGO on earnings quality, reporting a profit while its opponent remains loss making.
DCGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +3.7% |
| Q2 2026 | $73.4M | -8.7% |
| Q1 2026 | $75.6M | -21% |
| Q4 2025 | $74.9M | -38% |
| Q3 2025 | $70.8M | -49% |
| Q2 2025 | $80.4M | -51% |
| Q1 2025 | $96M | -50% |
| Q4 2024 | $120.8M | -39% |
DCGO's revenue has slid since its 2023 peak: $73M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +36 points |
| Q2 2026 | -24% | -2.7 points |
| Q1 2026 | -25% | -10 points |
| Q4 2025 | -140% | -133 points |
| Q3 2025 | -59% | -67 points |
| Q2 2025 | -22% | -28 points |
| Q1 2025 | -15% | -23 points |
| Q4 2024 | -6.2% | -12 points |
DCGO's operating margin was −24% last quarter, up 36 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DCGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DCGO on profitability, with a higher operating margin.
DCGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -578% |
| Q2 2026 | -$9.6M | -129% |
| Q1 2026 | -$5.1M | -162% |
| Q4 2025 | -$12M | -200% |
| Q3 2025 | $782.6K | -97% |
| Q2 2025 | $32.9M | +2.1% |
| Q1 2025 | $8.2M | +$19.8M |
| Q4 2024 | $12M | +$21.1M |
DCGO's free cash flow was −$30M over the past year, against $54M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DCGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +137K shares |
| 1 year | +1.2% | +1.1M shares |
| 3 years | -5.8% | -6.1M shares |
| 5 years | -1.1% | -1.1M shares |
DCGO has 99M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $5.1M |
| Q1 2025 | $5.8M |
| Q4 2024 | $2.7M |
DCGO hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DCGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DCGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -1.6x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -8.4x | Net Cash |
DCGO has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DCGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 4.2 | Oversold |
DCGO's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DCGO PE vs Healthcare Sector
| Metric | DCGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DCGO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DCGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 21% below |
| 20 week MA | $0.43 | 47% below |
| 50 week MA | $0.60 | 62% below |
| 100 week MA | $1.44 | 84% below |
| 200 week MA | $3.57 | 94% below |
DCGO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DCGO on trend strength, trading above more of its moving averages.
DCGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $10.4 | +0.8% |
| 2021 | $10.4 | $8.71 | -16% |
| 2022 | $8.71 | $6.91 | -21% |
| 2023 | $6.91 | $5.59 | -19% |
| 2024 | $5.59 | $4.38 | -22% |
| 2025 | $4.38 | $0.93 | -79% |
| 2026 YTD | $0.93 | $0.23 | -75% |
DCGO has finished five years in a row lower, and it's down 75% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DCGO on returns for 2026, with the stronger performance.